Blindness and bias in a trial of antidepressant medication for chronic tension-type headache

Cephalalgia

Volumn 26, Issue 8, 2006, Pages 973-982

  Holroyd, K A ^a,c   Tkachuk, G ^a,c   O'Donnell, F ^c   Cordingley, G E ^b  

^a OHIO UNIVERSITY   (United States)

^b OHIO UNIVERSITY   (United States)

^c Headache Treatment and Research   (United States)

Author keywords

Bias; Clinical trial; Double blind; Headache; Methodology

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; NORTRIPTYLINE; PLACEBO;

ADULT; ARTICLE; BEHAVIOR THERAPY; CHRONIC TENSION HEADACHE; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; FEMALE; HUMAN; INTERVENTION STUDY; MALE; METHODOLOGY; PATIENT PARTICIPATION; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; BIAS (EPIDEMIOLOGY); CONFOUNDING FACTORS (EPIDEMIOLOGY); DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OHIO; QUALITY ASSURANCE, HEALTH CARE; RANDOMIZED CONTROLLED TRIALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TENSION-TYPE HEADACHE; TREATMENT OUTCOME;

EID: 33746044963     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2006.01139.x     Document Type: Article

References (56)

1. Schulz K, Grimes D. Epidemiology series: blinding in randomized trials: hiding who got what. Lancet 2002; 359 (9307):696-700.
2. Gracely R, Dunbar R, Deeter W, Wolskee P. Clinician's expectations influence placebo analgesia. Lancet 1985; 1 (8419):43.
3. Schulz K, Chalmers L, Hayes R, Altman D. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273:408-12.
4. Swartzman L, Burkell J. Expectations and the placebo effect in clinical drug trials: why we should not turn a blind eye to unblinding, and other cautionary notes. Clin Pharamocol Ther 1998; 64:1-7.
5. Kirsch I, editor. How expectancies shape experience. Washington DC: American Psychological Association 1999.
6. Brownell K, Stunkard A. The double-blind in danger: untoward consequences of informed consent. Am J Psychiatry 1982; 139:1487-9.
7. White K, Kando J, Park T, Waternaux C, Brown WA. Side effects and the 'blindability' of clinical drug trials. Am J Psychiatry 1992; 149:1730-1.
8. Bystritsky A, Waikar S. Inert placebo versus active medication: patient blindability in clinical pharmacological trials. J Nerv Ment Dis 1994; 182:485-7.
9. Thomson R. Side effects and placebo amplification. Br J Psychiatry 1982; 140:64-8.
10. Basoglu M, Marks I, Livanou M, Swinson R. Double-blindness procedures, rater blindness, and ratings of outcome. Arch Gen Psychiatr 1997; 54:744-8.
11. Greenberg R, Bornstein R, Mj ZSF, Greenberg M. A meta-analysis of fluoxetine outcome in the treatment of depression. J Nerv Ment Dis 1994; 182:547-51.
12. Moncrieff J, Wesseley S, Hardy R. Meta-analysis of trials comparing antidepressants with active placebos. Br J Psychiatry 1998; 172:227-31.
13. Rabkin J, Markowitz J, Stewart J, McGrath P, Harrison W, Quitkin F et al. How blind is blind? Assessment of patient and doctor medication guesses in a placebo-controlled trial of imipramine and pheneizine. Psychiatry Res 1986; 19:75-86.
14. Quitkin F, Rabkin J, Gerald J, Davis J, Klein D. Validity of clinical trials of antidepressants. Am J Psychiatry 2000; 157:327-37.
15. Montori VM, Bhandari M, Devereauz PJ, Mannis BJ, Ghali WA, Guyatt GH. The reporting of blinding status in randomized controlled trials. J Clin Epidemiol 2002; 55:787-90.
16. Turner J, Jensen M, Warms C, Cardenas D. Blinding effectiveness and association of pretreatment expectations with pain improvement in a double-blind randomized controlled trial. Pain 2002; 99:91-9.
17. Bakker A, Spinhoven P, van Balkom A, Matser D, van Dyk R. Double-blindness procedure did not mask giving of medication in panic disorder. J Affect Dis 1999; 54:189-92.
18. Hughes J, Krahn D. Blindness and the validity of the double-blind procedure. J Clin Psychopharmacol 1985; 5:138-42.
19. Morin C, Colecchi C, Brink D, Astruc M, Mercer J, Remsberg S. How 'blind' are double-blind placebo-controlled trials of benzodiazopine hypnotics? Sleep 1995; 18:240-5.
20. Margraf J, Ehlers A, Roth W, Clark D. How 'blind' are double-blind studies? J Consult Clin Psychol 1991; 59:184-7.
21. Carroll K, Rounsaville B, Nich C. Blind man's bluff: effectiveness and significance of psychotherapy and pharmacotherapy blinding procedures in a clinical trial. J Consult Clin Psychol 1994; 62:276-80.
22. Marini J, Sheard M, Bridges C, Wagner E. An evaluation of the double-blind design in a study comparing lithium carbonate with placebo. Acta Psychiatr Scand 1976; 53:343-54.
23. Fisher S, Greenberg R. How sound is the double-blind design for evaluating psychotropic drugs? J Nerv Ment Dis 1993; 181:345-50.
24. Moncrieff J. Are antidepressants overrated? A review of methodological problems in antidepressant trials. J Nerv Ment Dis 2001; 189:288-95.
25. Antonuccio DO, Danton WG, DeNelsky GY, Greenberg RP, Gordon JS. Raising questions about antidepressants. Psychother Psychosom 1999; 68:3-14.
26. Fisher S, Greenberg R, editors. The limits of biological treatments for psychological distress: comparisons with psychotherapy and placebo. Hillsdale: Lawrence Erlbaum Associates 1989.
27. Greenberg RP, Bornstein R, Greenberg M, Fisher S. A meta-analysis of antidepressant outcome under 'blinder' conditions. J Consult Clin Psychol 1992; 60:664-9.
28. Kirsch I, Moore TJ, Scoboria A, Nicholls S. The emperor's new drugs: an analysis of antidepressant medication data submitted to the US Food and Drug Administration. Prevention & Treatment 2002; 5:23. Available from: http://www.journals.apa.org/prevention/volume5/pre0050023a.html Accessed 15 March 2006.
29. Kirsch I, Sapirstein G. Listening to Prozac but hearing placebo: a meta-analysis of antidepressant medication. In: Kirsch I, ed. How expectancies shape experience. Washington, DC: American Psychological Association 1999.
30. Petcova E, Quitkin F, McGrath P. A method to quantify rater bias in antidepressant trials. Neuropsychopharmacology 2000; 22:559-65.
31. Holroyd KA, O'Donnell FJ, Stensland M, Lipchik GL, Cordingley GE, Carlson B. Management of chronic tension-type headache with tricyclic antidepressant medication, stress-management therapy, and their combination: a randomized controlled trial. JAMA 2001; 285:2208-15.
32. Olesen JC. Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain. Headache Classification Committee of the International Headache Society. Cephalalgia 1988; 8 (Suppl. 7):1-96.
33. Silberstein S, Rosenberg J. Multispecialty consensus on diagnosis and treatment of headache. Neurology 2000; 54:1553-4.
34. Mathew NT, Bendtsen L. Prophylactic pharmacotherapy of tension-type headache. In: Olesen J, Tfelt-Hansen P, Welch KMA, editors. The headaches, 2nd edn. Philadelphia: Lippincott Williams & Wilkins 2000:667-74.
35. Ashina A, Ashina M. Current and potential future drug therapies for tension-type headache. Curr Pain Headache Rep 2003; 7:466-74.
36. Holroyd KA, French DJ, Nash JM, Tobin DL, Echelberger-McCune RL. Stress management for tension headaches: a treatment program for controlling headaches. Athens, OH: Ohio University Headache Project 1995.
37. Lipchik GL, Holroyd KA, Nash JM. Cognitive-behavioral management of recurrent headache disorders: a minimal-therapist contact approach. In: Turk DC, Gatchel RS, eds. Psychological approaches to pain management, 2nd edn. New York: Guilford Pubs 2002:356-89.
38. Blanchard EB, Andrasik F, Neff DF, Jurish SE, O'Keefe DM. Social validation of the headache diary. Behav Ther 1981; 12:711-5.
39. Holroyd KA, Malinoski P, Davis MK, Lipchik GL. The three dimensions of headache impact: pain, disability and affective distress. Pain 1999; 83:571-8.
40. Penzien D, Andrasik F, Freidenberg B, Houle T, Lake A, Lipchik G et al. Guidelines for trials of behavioral treatments for recurrent headache, first edition. American Headache Society Behavioral Clinical Trials Workgroup. Headache 2005;45 (Suppl. 2):S110-S132.
41. Schoenen J, Boureau F, Kunkel R. Guidelines for trials of drug treatments in tension-type headache. Cephalagia 1995; 15:165-79.
42. International Headache Society Clinical Trials Subcommittee. Guidelines for Controlled Trials of Drugs in Migraine, second edition. Cephalagia 2000;20:765-86.
43. Greenberg R, Fisher S. A second opinion: rethinking the claims of biological psychiatry. In: Fisher S, Greenberg R, editors. The limits of biological treatments for psychological distress: comparisons with psychotherapy and placebo. Hillsdale: Lawrence Erlbaum Associates 1989:309-36.
44. Andrasik F, Lipchick G, McCrory D, Wittrock D. Outcome measurement in behavioral headache research: headache parameters and psychosocial outcomes. Headache 2005; 45:429-37.
45. Erskine A, Morley S, Pearce S. Memory for pain: a review. Pain 1990; 41:255-65.
46. Sharpe L, Ryan B, Allard S, Sensky T. Testing for the integrity of blinding in clinical trials: how valid are forced choice paradigms? Psychother Psychosom 2003; 72:128-31.
47. Webb E, Campbell D, Schwartz D, Sechrest L. Unobtrusive measures: nonreactive research in social sciences. Chicago: Rand McNally 1966.
48. Bang H, Ni L, Davis C. Assessment of blinding in clinical trials. Control Clin Trials 2004; 25:143-6.
49. James K, Lee K, Kraemer H, Fuller R. An index for assessing blindness in a multicenter clinical trial: disulfiram for alcohol cessation - a VA cooperative study. Stat Med 1990; 15:1421-34.
50. Nash J, McCrory D, Nicholson R, Andrasik F. Efficacy and effectiveness approaches in behavioral treatment trials. Headache 2005; 45:507-12.
51. Rothrock J, Parada V, Sims C, Key K, Walters N, Zweifler R. The impact of intensive patient education on clinical outcome in a clinic-based migraine population. Headache 2005; 45:772-3.
52. Maizels M, Saenz V, Wirjo J. Impact of a group-based model of disease management for headache. Headache 2003; 43:621-7.
53. Stewart WF, Lipton RB, Kolodner K, Sawyer J, Lee C, Liberman J. Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain 2000; 88:41-52.
54. Holroyd KA, Nash JM, Pingel JD, Cordingley GE, Jerome A. A comparison of pharmacological (amitriptyline HCl) and nonpharmacological (cognitive- behavioral) therapies for chronic tension headaches. J Consult Clin Psychol 1991; 59:387-93.
55. Holroyd KA, Penzien DB. Pharmacological vs. nonpharmacological prophylaxis of recurrent migraine headache: a meta-analytic review of clinical trails. Pain 1990; 42:1-13.
56. Cahn T, Cram J. Changing measurement instrument at follow-up: a potential source of error. Biofeedback Self Regul 1980; 5:265-73.